---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-273563"
form_type: "8-K"
ticker: "CPRX"
cik: "0001369568"
company_name: "CATALYST PHARMACEUTICALS, INC."
filed_at: "2023-11-08T23:59:59+00:00"
generated_at: "2026-06-08T08:58:11.401902+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Catalyst Q3 net revenues $102.7M (+79% YoY); non-GAAP EPS $0.49; raises FY revenue guidance to $390-395M

## Summary
- GAAP net loss per diluted share $(0.29) reflects $81.5M one-time IPR&D expense from AGAMREE license acquisition.
- Non-GAAP net income $55.9M ($0.49 diluted), up 95% YoY; total net revenues increased 79% to $102.6M.
- FDA approved AGAMREE (vamorolone) for Duchenne muscular dystrophy; commercial launch expected Q1 2024.
- Raised full-year 2023 total revenue guidance to $390-$395M from prior $370-$380M.
- sNDA for FIRDAPSE maximum daily dose increase to 100 mg accepted for filing by FDA; two new FIRDAPSE patents allowed.

## SEC filing metadata
- accession: 0001193125-23-273563
- form_type: 8-K
- ticker: CPRX
- cik: 0001369568
- company_name: CATALYST PHARMACEUTICALS, INC.
- filed_at: 2023-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1369568/000119312523273563/0001193125-23-273563-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1369568/000119312523273563/d581027d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-273563
- JSON: https://secwatch.observer/filing/0001193125-23-273563.json
- Plain text: https://secwatch.observer/filing/0001193125-23-273563.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.